BACKGROUND & AIMS: Chronic kidney disease (CKD) can have a negative impact on the natural history of hepatitis C virus infection (HCV) infection; patients with HCV and CKD often have adverse outcomes. We evaluated a large and geographically diverse group of patients to determine whether HCV status has an independent effect on the risk of developing CKD. METHODS: We conducted a cohort study of 167,569 patients included in a national health care claims database from January 1, 2003-December 31, 2006, with a mean follow-up of 25.3 months. We used multivariable logistic regression analyses to measure the independent effect of HCV status on the baseline prevalence of and progression to CKD (estimated glomerular filtration rate, <60 mL/min/1.73 m(2)). RESULTS: The baseline prevalence of CKD was similar in patients with versus those without HCV (5.3% vs 5.1%, P = .3). Similarly, among patients with preserved renal function at baseline (n = 82,629), there was no difference in the overall progression to CKD in patients with versus those without HCV (3.8% vs 3.5%, P = .1). HCV status was not associated with progression to CKD, even after adjusting for patient demographics, comorbidities, and use of relevant medications (odds ratio, 0.92; 95% confidence interval, 0.79-1.08). CONCLUSIONS: We found no association between HCV and risk of development of CKD. These data are relevant in counseling HCV patients regarding the impact of HCV on renal function. Copyright (c) 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
BACKGROUND & AIMS:Chronic kidney disease (CKD) can have a negative impact on the natural history of hepatitis C virus infection (HCV) infection; patients with HCV and CKD often have adverse outcomes. We evaluated a large and geographically diverse group of patients to determine whether HCV status has an independent effect on the risk of developing CKD. METHODS: We conducted a cohort study of 167,569 patients included in a national health care claims database from January 1, 2003-December 31, 2006, with a mean follow-up of 25.3 months. We used multivariable logistic regression analyses to measure the independent effect of HCV status on the baseline prevalence of and progression to CKD (estimated glomerular filtration rate, <60 mL/min/1.73 m(2)). RESULTS: The baseline prevalence of CKD was similar in patients with versus those without HCV (5.3% vs 5.1%, P = .3). Similarly, among patients with preserved renal function at baseline (n = 82,629), there was no difference in the overall progression to CKD in patients with versus those without HCV (3.8% vs 3.5%, P = .1). HCV status was not associated with progression to CKD, even after adjusting for patient demographics, comorbidities, and use of relevant medications (odds ratio, 0.92; 95% confidence interval, 0.79-1.08). CONCLUSIONS: We found no association between HCV and risk of development of CKD. These data are relevant in counseling HCVpatients regarding the impact of HCV on renal function. Copyright (c) 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
Authors: M J Alter; D Kruszon-Moran; O V Nainan; G M McQuillan; F Gao; L A Moyer; R A Kaslow; H S Margolis Journal: N Engl J Med Date: 1999-08-19 Impact factor: 91.245
Authors: Lisa I Backus; Barbara R Phillips; Derek B Boothroyd; Larry A Mole; Jane Burgess; Michael O Rigsby; Sophia W Chang Journal: J Acquir Immune Defic Syndr Date: 2005-08-15 Impact factor: 3.731
Authors: Gregory L Armstrong; Annemarie Wasley; Edgar P Simard; Geraldine M McQuillan; Wendi L Kuhnert; Miriam J Alter Journal: Ann Intern Med Date: 2006-05-16 Impact factor: 25.391
Authors: Josef Coresh; Elizabeth Selvin; Lesley A Stevens; Jane Manzi; John W Kusek; Paul Eggers; Frederick Van Lente; Andrew S Levey Journal: JAMA Date: 2007-11-07 Impact factor: 56.272
Authors: Judith I Tsui; Eric Vittinghoff; Michael G Shlipak; Daniel Bertenthal; John Inadomi; Rudolph A Rodriguez; Ann M O'Hare Journal: Arch Intern Med Date: 2007-06-25
Authors: Takahiro Higashi; Neil S Wenger; John L Adams; Constance Fung; Martin Roland; Elizabeth A McGlynn; David Reeves; Steven M Asch; Eve A Kerr; Paul G Shekelle Journal: N Engl J Med Date: 2007-06-14 Impact factor: 91.245
Authors: Miklos Z Molnar; Hazem M Alhourani; Barry M Wall; Jun L Lu; Elani Streja; Kamyar Kalantar-Zadeh; Csaba P Kovesdy Journal: Hepatology Date: 2015-03-20 Impact factor: 17.425
Authors: Angela Sciacqua; Maria Perticone; Eliezer J Tassone; Antonio Cimellaro; Benedetto Caroleo; Sofia Miceli; Michele Andreucci; Anna Licata; Giorgio Sesti; Francesco Perticone Journal: Intern Emerg Med Date: 2015-11-23 Impact factor: 3.397
Authors: Sara Yee Tartof; Jin-Wen Hsu; Rong Wei; Kevin B Rubenstein; Haihong Hu; Jean Marie Arduino; Michael Horberg; Stephen F Derose; Lei Qian; Carla V Rodriguez Journal: Clin J Am Soc Nephrol Date: 2018-09-21 Impact factor: 8.237